OliX Pharmaceuticals, Inc. Logo

OliX Pharmaceuticals, Inc.

Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.

226950 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 고등동 608-3 -, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

OliX Pharmaceuticals, Inc. is a clinical-stage biotechnology company that specializes in the development of novel therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric small interfering RNA (asiRNA) platform to discover and advance next-generation nucleic acid-based treatments. Its development pipeline is focused on addressing diseases with high unmet medical needs, particularly in dermatology, ophthalmology, and metabolic disorders. Key programs in its pipeline target conditions such as hypertrophic scars, androgenetic alopecia (male-pattern baldness), age-related macular degeneration (AMD), and metabolic dysfunction-associated steatohepatitis (MASH). OliX aims to develop locally administrable therapies to improve safety and efficacy, positioning itself as an innovator in oligonucleotide therapeutics.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for OliX Pharmaceuticals, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.9 KB
2025-08-28 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.7 KB
2025-08-26 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.3 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 164.1 KB
2025-08-19 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 125.8 KB
2025-08-19 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.2 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 23.7 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.7 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.7 MB

Automate Your Workflow. Get a real-time feed of all OliX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for OliX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.